Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Barclays PLC

Barclays PLC increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 42.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,166 shares of the company's stock after acquiring an additional 8,385 shares during the period. Barclays PLC owned about 0.09% of Medpace worth $9,359,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of MEDP. Invesco Ltd. boosted its position in Medpace by 91.8% during the fourth quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock worth $360,387,000 after purchasing an additional 519,186 shares in the last quarter. Proficio Capital Partners LLC grew its holdings in Medpace by 34,497.4% in the 4th quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company's stock valued at $80,575,000 after buying an additional 241,827 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Medpace during the 4th quarter valued at about $78,144,000. Norges Bank acquired a new position in shares of Medpace during the 4th quarter valued at about $69,859,000. Finally, GW&K Investment Management LLC boosted its position in shares of Medpace by 93.9% during the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock valued at $91,516,000 after acquiring an additional 133,379 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Insiders Place Their Bets

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the sale, the director now directly owns 2,998 shares in the company, valued at $904,856.36. This represents a 36.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 20.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on MEDP. Leerink Partnrs raised shares of Medpace to a "hold" rating in a research report on Monday, March 24th. William Blair reaffirmed a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Truist Financial reduced their target price on shares of Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a report on Wednesday, April 23rd. Mizuho dropped their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Finally, Robert W. Baird dropped their price target on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. Eleven analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $349.30.

Medpace Stock Down 0.1 %

NASDAQ MEDP traded down $0.37 during trading hours on Monday, hitting $298.18. 390,361 shares of the stock were exchanged, compared to its average volume of 340,141. The company has a market cap of $8.57 billion, a price-to-earnings ratio of 23.61, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $459.77. The stock has a 50-day moving average of $312.88 and a 200 day moving average of $331.26.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The company had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. During the same period in the prior year, the business posted $3.20 earnings per share. On average, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.